Plug Power Inc vs Viatris Inc — how do they compare? Plug Power Inc trades at $2.24 (market cap $2.98B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 6.9× Plug Power Inc's market cap, and Viatris Inc pays a 2.73% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals.
| PLUG | VTRS | |
|---|---|---|
Market Cap | $2.98B | $20.50B |
Sector | Industrials | Health |
52-Week High | $4.14 | $17.59 |
52-Week Low | $1.40 | $8.74 |
Enterprise Value | $3.77B | $32.71B |
Dividend Yield | — | 2.73% |
Signals from Pluang's Aura AI — not financial advice
Plug Power (PLUG) trades at $2.27, up 5.58% on the day, but remains in a bearish technical trend with oversold RSI readings. The company shows persistent unprofitability with a -227.13% net margin and negative cash flows, though recent earnings have beaten estimates in two of the last three quarters. Positive developments include a 50-megawatt electrolyzer order in Australia and strategic asset sales aimed at boosting liquidity by over $275 million, providing some operational momentum amid financial challenges.
The outlook remains high-risk due to deep losses and cash burn, but analyst consensus is cautiously optimistic with a $2.92 price target (28% upside). Investment opportunity hinges on successful turnaround execution and hydrogen demand growth, while key risks include continued dilution, competitive pressure, and reliance on financing to fund operations. The stock's depressed valuation reflects significant skepticism, leaving room for volatility on news flow.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Trailing returns across standard periods
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →